Consortium
PSYCHIATRICUM

APPENDIX. SUPPLEMENTARY DATA TO:

Aleksandr Reznik, Timur Syunyakov, Inessa Akhmerova, Daniil Butylin, Anastasia Vasilenko, Anton Gvozdetckii, Tagir Gizatullin, Galina Gilmanshina, Egor Golosov, Sergey Kolchev, Lidiya Linova, Daniil Miron, Aleksandr Mudrak, Igor Oleichik, Stepan Sizov, Elena Tarakanova, Olga Chesnokova.

Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression.
Consortium Psychiatricum 2022; published online September 2022.
DOI: 10.17816/CP172.

This appendix is a part of the original submission.
The appendix is posted as it was supplied by the authors.

Table S1. Incidence of adverse events in the study

Adverse events	*n*	%
akathisia	22	13%
nausea	19	11%
tremor	14	8%
drowsiness	12	7%
headache	11	7%
sleep disorder	8	5%
dizziness	7	4%
anxiety	7	4%
vomiting	6	4%
weakness	4	2%
dry mouth	4	2%
sweating	3	2%
anemia	2	1%
heartburn	2	1%
tachycardia	2	1%
abdominal pain	2	1%
arousal	2	1%
weight gain	2	1%
hypersalivation	1	1%
hypersedation	1	1%
nausea, vomiting	1	1%
muscle rigidity	1	1%
pneumonia	1	1%
acute dystonia	1	1%
nausea, abdominal discomfort	1	1%
fatigue	1	1%
hypokinesia	1	1%
seizures	1	1%
diarrhea	1	1%
indigestion	1	1%
acute dystonia	1	1%
parkinsonism	1	1%
Total	143	100%

Table S2. Association of the frequency of types of adverse events with the weighted average daily dose

AE type	40–80 mg	80–120 mg	120–160 mg	Total
EPS	5 (71.4%)	16 (22.9%)	20 (30.3%)	41 (28.7%)
General symptoms	0 (0%)	19 (27.1%)	15 (22.7%)	34 (23.8%)
GI tract	0 (0%)	17 (24.3%)	16 (24.2%)	33 (23.1%)
Stimulating effect	0 (0%)	9 (12.9%)	8 (12.1%)	17 (11.9%)
Autonomic AEs	1 (14.3%)	7 (10%)	2 (3%)	10 (7%)
Hematological	0 (0%)	1 (1.4%)	1 (1.5%)	2 (1.4%)
Sedation	0 (0%)	1 (1.4%)	1 (1.5%)	2 (1.4%)
Metabolic	0 (0%)	0 (0%)	2 (3%)	2 (1.4%)
Infectious disease	1 (14.3%)	0 (0%)	0 (0%)	1 (0.7%)
Seizures	0 (0%)	0 (0%)	1 (1.5%)	1 (0.7%)
Total	**7 (100%)**	**70 (100%)**	**66 (100%)**	**143 (100%)**